Pancreatic Cancer Research

ResearcherJapan Agency for Medical Research and DevelopmentActive in the last 2 years

Chigusa Morizane

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-6560-7503; OpenAlex author ID A5005262911. Sources: OpenAlex.

Their work

Papers
58 (first author 13, last author 6)
Trials
0
Grants
0
Labs led
1
Collaborators
170
Papers, trials and grants by year

2011: 1 paper · 2012: 4 papers · 2013: none · 2014: none · 2015: 4 papers · 2016: 3 papers · 2017: 3 papers · 2018: 1 paper · 2019: 4 papers · 2020: 2 papers · 2021: 2 papers · 2022: 8 papers · 2023: 7 papers · 2024: 9 papers · 2025: 7 papers · 2026: 3 papers

Papers 50 of 58

  1. NALIRIFOX in Japanese treatment-naïve patients with metastatic pancreatic adenocarcinoma: results from an open-label, phase II study. Co-author DOI 10.1016/j.esmogo.2026.100365↗
  2. Clinical Practice Guidelines for Pancreatic Cancer 2025 From the Japan Pancreas Society: A Synopsis. Co-author DOI 10.1097/mpa.0000000000002600↗
  3. KRAS Mutations in Duodenal Lavage Fluid After Secretin Stimulation for Detection of Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006645↗
  4. Electronic Patient-Reported Outcome Quality of Life Score in Japanese Patients With Pancreatic Cancer on Second-Line Chemotherapy: A Multicenter Observational … Co-author DOI 10.1002/cam4.71161↗
  5. Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world study using inverse probability of trea… Co-author DOI 10.1007/s00535-024-02186-9↗
  6. Correction: Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world study using inverse probabi… Co-author DOI 10.1007/s00535-025-02215-1↗
  7. Diagnosis and treatment strategies for hereditary pancreatic cancer syndrome. First author DOI 10.1007/s10147-025-02905-z↗
  8. Outcomes of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in patients with early recurrent pancreatic cancer after adjuvant S-1 treatment: A propensity sco… Co-author DOI 10.1016/j.pan.2025.08.017↗
  9. Platform of single-molecule enzyme activity-based liquid biopsy for detection of pancreatic adenocarcinoma at early stages Co-author DOI 10.1101/2025.08.07.669035↗
  10. Third-line S-1 or FOLFOX treatment in advanced pancreatic cancer who received gemcitabine+nab-paclitaxel and nanoliposomal-irinotecan+5-fluorouracil/leucovorin Co-author DOI 10.21203/rs.3.rs-5801148/v1↗
  11. Prevalence of HER3 Expression in Pancreatic Cancer Patients Treated With Systemic Chemotherapy. First author DOI 10.1002/cam4.70474↗
  12. Clinical development of a blood biomarker using apolipoprotein-A2 isoforms for early detection of pancreatic cancer. Co-author DOI 10.1007/s00535-023-02072-w↗
  13. Familial and hereditary pancreatic cancer in Japan. First author DOI 10.1007/s10689-024-00395-y↗
  14. Early tumor shrinkage as a prognostic predictor in chemotherapy-naïve patients with locally advanced pancreatic cancer treated with modified FOLFIRINOX or gemc… Co-author DOI 10.1016/j.pan.2024.07.006↗
  15. Clinical utility of BRCA and ATM mutation status in circulating tumour DNA for treatment selection in advanced pancreatic cancer. Last author DOI 10.1038/s41416-024-02834-0↗
  16. A Phase 2 study of nivolumab in combination with modified FOLFIRINOX for metastatic pancreatic cancer. Co-author DOI 10.1038/s44276-023-00028-4↗
  17. Protocol digest of a randomized phase III trial comparing S-1-based chemoradiotherapy with/without nivolumab for unresectable locally advanced or borderline re… Co-author DOI 10.1093/jjco/hyae084↗
  18. Brightline-2: a phase IIa/IIb trial of brigimadlin (BI 907828) in advanced biliary tract cancer, pancreatic ductal adenocarcinoma or other solid tumors. Last author DOI 10.2217/fon-2023-0963↗
  19. Study Protocol for a Prospective Self-Controlled Trial on Success in Meeting Comprehensive Genomic Profiling Analysis Criteria for Specimens Obtained by Endosc… Co-author DOI 10.3390/diseases12080182↗
  20. Correction: The epidemiology of rare types of hepatobiliary and pancreatic cancer from national cancer registry. First author DOI 10.1007/s00535-022-01944-x↗
  21. Clinical Practice Guidelines for Pancreatic Cancer 2022 from the Japan Pancreas Society: a synopsis. Co-author DOI 10.1007/s10147-023-02317-x↗
  22. Clinical features of germline BRCA1/2 or ATM pathogenic variant positive pancreatic cancer in Japan. First author DOI 10.1016/j.pan.2023.10.017↗
  23. Clinical significance of circulating-tumour DNA analysis by metastatic sites in pancreatic cancer. Last author DOI 10.1038/s41416-023-02189-y↗
  24. Efficient and accurate KRAS genotyping using digital PCR combined with melting curve analysis for ctDNA from pancreatic cancer patients. Co-author DOI 10.1038/s41598-023-30131-y↗
  25. Fine-needle biopsy with 19G needle is effective in combination with endoscopic ultrasound-guided tissue acquisition for genomic profiling of unresectable pancr… Co-author DOI 10.1111/den.14423↗
  26. [Systemic chemotherapy for metastatic pancreatic cancer]. Co-author DOI 10.11405/nisshoshi.120.651↗
  27. The epidemiology of rare types of hepatobiliary and pancreatic cancer from national cancer registry. First author DOI 10.1007/s00535-022-01920-5↗
  28. Proportion of unresectable pancreatic cancer specimens obtained by endoscopic ultrasound-guided tissue acquisition meeting the OncoGuide™ NCC Oncopanel System … Co-author DOI 10.1007/s00535-022-01926-z↗
  29. The influence of UGT1A1 polymorphisms on modified FOLFIRINOX dose in double-variant-type patients with advanced pancreatic cancer. First author DOI 10.1007/s10147-022-02186-w↗
  30. Safety and efficacy of S-IROX (S-1, irinotecan and oxaliplatin combination therapy) in patients with advanced pancreatic cancer: A multicenter phase 1b dose-es… Co-author DOI 10.1016/j.ejca.2022.06.010↗
  31. Study protocol for a multi-institutional prospective surveillance study among kindreds with familial pancreatic cancer and individuals with hereditary pancreat… First author DOI 10.1016/j.pan.2022.04.006↗
  32. Endoscopic duodenal stent placement versus gastrojejunostomy for unresectable pancreatic cancer patients with duodenal stenosis before introduction of initial … Co-author DOI 10.1093/jjco/hyab194↗
  33. Germline variants in cancer-predisposing genes in pancreatic cancer patients with a family history of cancer. First author DOI 10.1093/jjco/hyac110↗
  34. Whole-exome Sequencing Reveals New Potential Susceptibility Genes for Japanese Familial Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000004213↗
  35. FOLFIRINOX in advanced pancreatic cancer patients with the double-variant type of UGT1A1 *28 and *6 polymorphism: a multicenter, retrospective study. Co-author DOI 10.1007/s00280-020-04206-w↗
  36. A phase II study of FOLFIRINOX with primary prophylactic pegfilgrastim for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer. Co-author DOI 10.1007/s10147-021-02001-y↗
  37. Phase II clinical trial of gemcitabine plus oxaliplatin in patients with metastatic pancreatic adenocarcinoma with a family history of pancreatic/breast/ovaria… First author DOI 10.1007/s10147-020-01721-x↗
  38. O-Glycan-Altered Extracellular Vesicles: A Specific Serum Marker Elevated in Pancreatic Cancer. Co-author DOI 10.3390/cancers12092469↗
  39. Phase I study of resminostat, an HDAC inhibitor, combined with S-1 in patients with pre-treated biliary tract or pancreatic cancer. Last author DOI 10.1007/s10637-018-0634-5↗
  40. Impact of the Duration of Diabetes Mellitus on the Outcome of Metastatic Pancreatic Cancer Treated with Gemcitabine: A Retrospective Study. Co-author DOI 10.2169/internalmedicine.2539-18↗
  41. Genomic Features and Clinical Management of Patients with Hereditary Pancreatic Cancer Syndromes and Familial Pancreatic Cancer. Last author DOI 10.3390/ijms20030561↗
  42. Familial Pancreatic Cancer and Surveillance of High-Risk Individuals. Co-author DOI 10.5009/gnl18449↗
  43. Germline variants in pancreatic cancer patients with a personal or family history of cancer fulfilling the revised Bethesda guidelines. First author DOI 10.1007/s00535-018-1466-y↗
  44. Utility of Assessing the Number of Mutated KRAS, CDKN2A, TP53, and SMAD4 Genes Using a Targeted Deep Sequencing Assay as a Prognostic Biomarker for Pancreatic … Co-author DOI 10.1097/mpa.0000000000000760↗
  45. An Oncogenic ALK Fusion and an RRAS Mutation in KRAS Mutation-Negative Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1634/theoncologist.2016-0194↗
  46. Familial pancreatic cancer: Concept, management and issues. Co-author DOI 10.3748/wjg.v23.i6.935↗
  47. C-Reactive Protein Level Is an Indicator of the Aggressiveness of Advanced Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000000465↗
  48. Clinicopathologic Features and Germline Sequence Variants in Young Patients (≤40 Years Old) With Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1097/mpa.0000000000000574↗
  49. Germline mutations in Japanese familial pancreatic cancer patients. Co-author DOI 10.18632/oncotarget.12490↗
  50. ACTN4 copy number increase as a predictive biomarker for chemoradiotherapy of locally advanced pancreatic cancer. Co-author DOI 10.1038/bjc.2014.623↗

Closest collaborators

The 25 strongest of 170 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Takuji Okusaka · 32 shared papers, 2011–2025 · strength 3.39
  2. Masafumi Ikeda · 21 shared papers, 2011–2025 · strength 2.39
  3. Makoto Ueno · 16 shared papers, 2012–2025 · strength 2.29
  4. Junji Furuse · 16 shared papers, 2012–2025 · strength 2.14
  5. Susumu Hijioka · 12 shared papers, 2017–2026 · strength 1.95
  6. Akihiro Ohba · 11 shared papers, 2021–2025 · strength 1.72
  7. Masato Ozaka · 8 shared papers, 2022–2026 · strength 1.55
  8. Takeshi Terashima · 9 shared papers, 2017–2026 · strength 1.41
  9. Naohiro Okano · 9 shared papers, 2020–2025 · strength 1.33
  10. Nobumasa Mizuno · 9 shared papers, 2017–2026 · strength 1.25
  11. Hideki Ueno · 14 shared papers, 2011–2024 · strength 1.12
  12. Shinichi Yachida · 10 shared papers, 2015–2026 · strength 1.06
  13. Hiroyuki Matsubayashi · 4 shared papers, 2017–2025 · strength 0.97
  14. Yasuyuki Kawamoto · 6 shared papers, 2022–2025 · strength 0.90
  15. Kumiko Umemoto · 6 shared papers, 2021–2025 · strength 0.90
  16. Satoshi Kobayashi · 6 shared papers, 2021–2025 · strength 0.89
  17. Hiroshi Imaoka · 6 shared papers, 2019–2025 · strength 0.88
  18. Masayuki Kitano · 4 shared papers, 2017–2026 · strength 0.84
  19. Kunihiro Tsuji · 6 shared papers, 2020–2025 · strength 0.83
  20. Tomoyuki Satake · 4 shared papers, 2022–2024 · strength 0.76
  21. Satoshi Nara · 6 shared papers, 2012–2025 · strength 0.70
  22. Akinori Asagi · 5 shared papers, 2020–2025 · strength 0.67
  23. Hiroaki Nagano · 4 shared papers, 2022–2026 · strength 0.66
  24. Kenji Ikezawa · 3 shared papers, 2025–2026 · strength 0.65
  25. Mitsuhito Sasaki · 5 shared papers, 2019–2026 · strength 0.63

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.